Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

NCT04546724 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4128

Enrollment

INDUSTRY

Sponsor class

Conditions

Chikungunya Virus Infection

Interventions

BIOLOGICAL: VLA1553
BIOLOGICAL: Placebo

Sponsor

Valneva Austria GmbH